LSL Pharma Group Inc (LSL) Financial Statements
LSL Pharma Group Inc Financial Overview
LSL Pharma Group Inc's market cap is currently $39.92M. The company's EPS TTM is ―; its P/E ratio is -5.38; LSL Pharma Group Inc is estimated to report earnings on December 1, 2026, and the estimated EPS forecast is $-0.02. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 23 | Jul 22 | Dec 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | $ 1.65M | ― | $ 2.53M | $ 943.03K | $ 507.58K |
| Operating Income | $ -6.67M | $ -70.85K | $ -65.27K | $ 564.05K | $ 809.27K |
| EBITDA | $ -5.77M | $ -70.85K | $ 931.55K | $ 747.58K | $ 990.62K |
| Net Income | $ -8.47M | $ -74.22K | $ -1.78M | $ 152.47K | $ 88.01K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ― | ― | ― | ― | ― |
| Total Assets | $ 30.90M | $ 25.51K | $ 29.03M | $ 27.18M | $ 23.79M |
| Total Debt | $ 15.74M | $ 0.00 | $ 12.74M | $ 10.57M | $ 10.57M |
| Net Debt | $ 15.73M | $ -288.00 | $ 12.00M | $ 8.64M | $ 10.11M |
| Total Liabilities | $ 22.25M | $ 285.47K | $ 17.92M | $ 16.84M | $ 16.31M |
| Stockholders' Equity | ― | ― | ― | ― | ― |
| Cash Flow | |||||
| Free Cash Flow | $ -8.09M | $ -3.21K | $ -2.00M | $ -1.12M | $ -203.35K |
| Operating Cash Flow | ― | ― | ― | ― | ― |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
Currency in USD